Back to Journals » Therapeutics and Clinical Risk Management » Volume 18 » A Health Technology Assessment Based on Chinese Guidelines: Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Type 2 Diabetes Complicated with Cardiovascular Disease
Please verify you are not a robot.